|
|
Post by vissertrades on Jul 17, 2014 9:04:27 GMT -5
Thanks and sorry for the re-post!
|
|
|
|
Post by chauffe00 on Aug 7, 2014 23:12:42 GMT -5
RBC Capital Outperform, 16.00 Target
MannKind Afrezza label largely as expected, says RBC Capital
After the FDA approved Mannkind's Afrezza, RBC Capital thinks most of the label, including warnings against use in COPD, etc., and for lung function testing, are as expected. The firm believes that the company's ability to find a marketing partner for the drug will be a key factor in determining its potential. The firm expects the company to find a partner and it keeps an Outperform rating on the shares its only been a little over a month...so hmmmm?  |
|
|
|
Post by 4Balance on Aug 7, 2014 23:22:41 GMT -5
I'm not expecting an announcement in the next few days...but, far more likely, by end of month.
|
|
|
|
Post by BD on Aug 11, 2014 7:43:11 GMT -5
07:45 EDT MNKD theflyonthewall.com: MannKind partnership likely to be viewed favorably, says Piper Jaffray
Piper Jaffray views MannKind's (MNKD) partnership with Sanofi (SNY) for Afrezza as impressive given the "meaningful" upfront payment, shared economics and an advance of expenses up to $175M. Piper believes investors will view the partner and terms favorably and keeps a Neutral rating on shares of MannKind. :theflyonthewall.com
|
|
|
|
Post by chauffe00 on Aug 11, 2014 8:13:10 GMT -5
virtually all the analysts on the conference call have said CONGRATS ON THE GREAT DEAL!!!  |
|
|
|
Post by otherottawaguy on Aug 11, 2014 15:33:20 GMT -5
Keith A. Markey, Ph.D., M.B.A.
kmarkey@griffinsecurities.com
Stock Symbol NASDAQ: MNKD
Current Price $8.59
12 mos. Target Price $16.25
Market Cap $3,259.4 mln
Shares O/S 388.6 mln
Avg Daily Vol. (3 mos.) 10,522,488 shs.
52-Week Price Low/High $3.80 - $11.48
Fiscal Year End Dec
EPS
FY 13A FY 14E FY 15E
Q1 (Mar) $(0.15)A $(0.14)A $(0.14)E
Q2 (Jun) (0.16)A (0.19)A (0.11)E
Q3 (Sep) (0.17)A 0.16E (0.06)E
Q4 (Dec) (0.16)A (0.19)E 0.06E
$(0.64)A $(0.36)E $(0.25)E
August 11, 2014
MannKind Corp. BUY
Target Price Change : Pharmaceuticals
MannKind Partners with Sanofi Worldwide
Sanofi brings the right mix of diabetes drugs and marketing
experience. MannKind’s partner has an established presence in
the diabetes space with its long-acting basal insulin Lantus® and
a small number of other medicines that control blood glucose
levels. These drugs are sold in 122 countries with the support
of a salesforce numbering more than 1832,000. As a result,
the selection of Sanofi to market Afrezza® greatly reduces the
commercialization risk, in our opinion. Then, too, the company
has an established track record for introducing innovative drug
delivery systems, as evidenced by its introduction of the first
prefilled needle/syringe combination with its anti-thrombotic agent
Lovenox®. This also shows that its salesforce is comfortable
selling a product based on both its therapeutic value and the
simplicity of the delivery system.
We like the financial implications of the deal for MannKind.
The terms include an upfront payment of $150 million, $775 million
of milestones, and 35% of the profits from Afrezza. Commercial
launch is targeted for the March quarter, but MannKind will
likely book the first of many milestones before that. Triggers
for the milestones include manufacturing achievements, product
launches in Europe and Japan, and annual sales. (The first sales
milestone is at $250 million in business.) The Company will be
responsible for its share of the losses in the drug’s first days on
the market, but a loan facility will cover that expense probably until
profits from Afrezza are sufficient to repay the loan. Meanwhile,
Sanofi will assume responsibility for conducting clinical trials and
regulatory submissions.
MannKind is reviewing its options. With the signing of the
Afrezza marketing agreement, the Company has ample cash
to finance operations into 2016, based on its present structure
and projected obligations. Accordingly, management has already
begun to consider other opportunities, including expanding the
use of its Technosphere® particle technology internally and
through agreements with other companies. Approval of Afrezza
has already shown that regulators are comfortable with the
inhalable delivery system, thereby opening the door for other
medicines.
This stock’s risk-reward balance has just improved once
again. By partnering with Sanofi, MannKind has engaged a
proven marketer in the global diabetes arena and one that
can leverage the very attractive combination of Afrezza and
a long-acting basal insulin. We are maintaining our BUY
recommendation and have raised our price target to $16.25.
|
|
|
|
Post by seanismorris on Aug 11, 2014 15:44:11 GMT -5
Doesn't that guy working for TheStreet have an Ph.D. and M.B.A.?
No? Ok, then moving on.
Plus One for the Bulls
|
|
|
|
Post by 4Balance on Aug 11, 2014 16:49:05 GMT -5
virtually all the analysts on the conference call have said CONGRATS ON THE GREAT DEAL!!! Even Josh Schwimmer....! (M.D., Piper Jafray...stuck it to us a few months ago) |
|
|
|
Post by BD on Aug 11, 2014 16:56:43 GMT -5
15:51 EDT MNKD theflyonthewall.com: MannKind price target raised to $10 from $6.50 at Piper Jaffray
Piper Jaffray raised its price target for MannKind (MNKD) shares to $10 citing increased Afrezza penetration estimates following the company's deal with Sanofi (SNY). Piper views the deal as a positive but keeps a Neutral rating on MannKind pending a better entry point into the name. :theflyonthewall.com
|
|
|
|
Post by dreamboatcruise on Aug 11, 2014 18:42:44 GMT -5
So are there only two analyst updates so far since the announcement... one at $10 and one at $16.25?
|
|
|
|
Post by brentie on Aug 12, 2014 8:30:29 GMT -5
|
|
|
|
Post by brentie on Aug 12, 2014 9:53:01 GMT -5
Did MannKind Find Right Afrezza Partner in Sanofi? MannKind Corporation (NASDAQ:MNKD): Why The Stock Tumbled Despite Good News? Yes, say RBC analyst Adnan Butt and team who like the pairing of MannKind Corporation(NASDAQ:MNKD) and Sanofi (SNY) to market MannKind’s inhaled insulin: We continue to believe Sanofi is the right partner to market Afrezza for a variety of reasons…Sanofi knows the insulin market, can manufacture it, sells a broad array of diabetes focused products to endocrinologists and PCPs, and believes Afrezza can be used in broad set of patients, including 1) those who are insulin naïve, 2) those taking multiple injections, and 3) in combination with Sanofi’s products. MannKind selected Sanofi as a partner and that to us reflects a certain alignment in how the two partners view the market opportunity and selling strategy, the two questions the Street fixated on today. Financial terms are solid, Sanofi’s commitment could become even more apparent once post-marketing, label expansion, and market access studies and strategies become apparent… Sanofi is a stronger marketing partner than we expected so initial ramp could be quicker than forecast. Notably, MannKind’s profit split continues as long as Afrezza stays on the market, which could well be beyond the patent life. Lastly, Sanofi has right to first negotiation for MannKind’s inhaled GLP-1 and MannKind could also develop a pipeline now. Shares of MannKind have dropped 11% to $7.56 at 10:08 a.m. today after gaining yesterday 4.9% yesterday, while Sanofi is off 0.7% at $51.74. www.marketnewscall.com/mannkind-corporation-nasdaqmnkd-why-the-stock-tumbled-despite-good-news/1235685/ |
|
|
|
Post by garrett on Aug 12, 2014 13:25:42 GMT -5
So are there only two analyst updates so far since the announcement... one at $10 and one at $16.25? I think they are both right albeit one more conservative than the other - it's a matter "when" not "If" |
|
|
|
Post by brentie on Aug 12, 2014 13:53:59 GMT -5
|
|
|
|
Post by dreamboatcruise on Aug 12, 2014 15:59:33 GMT -5
I would think now that MNKD has been brought into the Sanofi diabetes fold it would get lots of new analyst coverage. Anyone have insight into whether that assumption is true and when it might happen?
|
|
